CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: ZNF737 (ImmuneEditome ID:100129842)

1. Gene summary of enriched editing regions for ZNF737

check button Gene summary
Gene informationGene symbol

ZNF737

Gene ID

100129842

GeneSynonymsZNF102
GeneCytomap

19p12

GeneTypeprotein-coding
GeneDescriptionzinc finger protein 737|zinc finger protein 102 (Y3)
GeneModificationdate20230329
UniprotIDO75373;M0R1M3;M0R1D1;M0QZS4
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr19:20536516-20537836:-ENST00000596530.1ENSG00000237440.7ZNF737intronicAluSx1,AluSx4,AluSg4,AluSq2chr19:20536516-20537836:-.alignment
chr19:20539012-20539300:-ENST00000596530.1ENSG00000237440.7ZNF737intronicAluSx1chr19:20539012-20539300:-.alignment
chr19:20540507-20542531:-ENST00000596530.1ENSG00000237440.7ZNF737intronicAluSz,AluSg,L1MA2,AluSpchr19:20540507-20542531:-.alignment


Top

2. Tumor-specific enriched editing regions for ZNF737


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
ENSG00000237440.7,ZNF737KICHEAG3.9789e-02image
chr19:20539012-20539300:-THCAEER2.2623e-06image
ENSG00000237440.7,ZNF737THCAEAG7.7303e-06image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
chr19:20540507-20542531:-KIRCPathEER2.5689e-023.2482e-020.1205image
ENSG00000237440.7,ZNF737THCAPathEAG6.3804e-064.0480e-040.1615image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
chr19:20540507-20542531:-GBMEER3.6297e-021.6153e-022.8422e+01image
ENSG00000237440.7,ZNF737SARCEAG4.0403e-021.4832e-032.5268e+03image

Top

3. Enriched editing regions and immune related genes for ZNF737


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark

More results



Top

4. Enriched editing regions and immune related splicing for ZNF737


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
ENSG00000237440.7,ZNF737
PCPGEAGA5ENSG00000002933.3chr7150804826:150804936:150804361:150804485:150804361:150804719-0.21822.5472e-028.7062e-06-0.4226imageNADAR;DKC1;FUS;HNRNPA2B1;TAF15NAMacrophages_M1GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
ENSG00000237440.7,ZNF737
TGCTEAGA3ENSG00000140451.8chr1564822265:64822391:64820981:64821520:64820981:648221320.35352.4125e-047.9764e-070.4466imageNADAR;BUD13;CSTF2T;DDX54;ELAVL1;FBL;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPL;HNRNPM;IGF2BP2;IGF2BP3;LIN28A;MOV10;MSI2;NOP58;PRPF8;PTBP1;RBFOX2;SRSF1;SRSF9;TAF15;TARDBP;U2AF2;UPF1NAB_cells_naiveGSVA_HALLMARK_GLYCOLYSIS
ENSG00000237440.7,ZNF737
TGCTEAGA5ENSG00000107263.14chr9131643238:131643417:131650809:131650949:131650128:1316509490.31242.0146e-021.6370e-060.4281imageNADAR;BUD13;CSTF2T;DDX54;DKC1;ELAVL1;FBL;FUS;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPL;HNRNPM;IGF2BP2;IGF2BP3;KHDRBS2;LIN28A;MBNL2;MOV10;MSI2;NOP58;PRPF8;PTBP1;RBFOX2;SRSF1;SRSF9;TAF15;TARDBP;U2AF2;UPF1NAMacrophages_M2GSVA_HALLMARK_ANGIOGENESIS
ENSG00000237440.7,ZNF737
TGCTEAGESENSG00000151914.13chr656466077:56466195:56468981:56468999:56469882:564699560.29494.6675e-023.4448e-060.4016imageNADAR;BUD13;CSTF2T;DDX54;DKC1;ELAVL1;FBL;FUS;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPL;HNRNPM;IGF2BP2;IGF2BP3;KHDRBS2;LIN28A;MBNL2;MOV10;MSI2;NOP58;PRPF8;PTBP1;RBFOX2;SRSF1;SRSF9;TAF15;TARDBP;U2AF2;UPF1DSTMacrophages_M2GSVA_HALLMARK_MYOGENESIS
ENSG00000237440.7,ZNF737
TGCTEAGIRENSG00000073169.9chr2250200978:50205024:50206316:502064620.37063.0311e-034.0322e-060.4116imageNADAR;BUD13;CSTF2T;DDX54;DKC1;ELAVL1;FBL;FUS;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPL;HNRNPM;IGF2BP2;IGF2BP3;KHDRBS2;LIN28A;MOV10;MSI2;NOP58;PRPF8;PTBP1;RBFOX2;SRSF1;SRSF9;TAF15;TARDBP;U2AF2;UPF1NAMacrophages_M2GSVA_HALLMARK_MYC_TARGETS_V2
ENSG00000237440.7,ZNF737
TGCTEAGA3ENSG00000175866.11chr1781108474:81108509:81115769:81115817:81110913:811158170.37644.1118e-038.2272e-070.4274imageNADAR;BUD13;CSTF2T;DDX54;DKC1;ELAVL1;FBL;FUS;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPL;HNRNPM;IGF2BP2;IGF2BP3;MBNL2;MOV10;MSI2;NOP58;PRPF8;PTBP1;RBFOX2;SRSF1;SRSF9;TAF15;TARDBP;U2AF2;UPF1NAMacrophages_M2GSVA_HALLMARK_PANCREAS_BETA_CELLS
ENSG00000237440.7,ZNF737
TGCTEAGESENSG00000175866.11chr1781108474:81108509:81110913:81110959:81115769:81115817-0.37664.1121e-037.7907e-07-0.4282imageNADAR;BUD13;CSTF2T;DDX54;DKC1;ELAVL1;FBL;FUS;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPL;HNRNPM;IGF2BP2;IGF2BP3;MBNL2;MOV10;MSI2;NOP58;PRPF8;PTBP1;RBFOX2;SRSF1;SRSF9;TAF15;TARDBP;U2AF2;UPF1NAMacrophages_M2GSVA_HALLMARK_PANCREAS_BETA_CELLS
ENSG00000237440.7,ZNF737
TGCTEAGA5ENSG00000185379.16chr1735106440:35106481:35107365:35107447:35106987:351074470.29987.6976e-034.8877e-060.4099imageNADAR;BUD13;CSTF2T;DDX54;DKC1;ELAVL1;FBL;FUS;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPL;HNRNPM;IGF2BP2;IGF2BP3;KHDRBS2;LIN28A;MBNL2;MOV10;MSI2;NOP58;PRPF8;PTBP1;RBFOX2;SRSF1;SRSF9;TAF15;TARDBP;U2AF2;UPF1NAMacrophages_M2GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
ENSG00000237440.7,ZNF737
TGCTEAGIRENSG00000156990.10chr39840681:9840805:9841982:98420820.35711.0851e-026.1516e-070.4286imageNADAR;BUD13;CSTF2T;DDX54;DKC1;ELAVL1;FBL;FUS;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPL;HNRNPM;IGF2BP2;IGF2BP3;KHDRBS2;LIN28A;MOV10;MSI2;NOP58;PRPF8;PTBP1;RBFOX2;SRSF1;SRSF9;TAF15;TARDBP;U2AF2;UPF1NAB_cells_naiveGSVA_HALLMARK_PANCREAS_BETA_CELLS
ENSG00000237440.7,ZNF737
TGCTEAGA3ENSG00000058272.11chr1279807225:79807330:79805591:79805768:79805591:79806333-0.37579.3585e-047.2652e-06-0.4185imageNADAR;BUD13;CSTF2T;DDX54;DKC1;ELAVL1;FBL;FUS;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPL;HNRNPM;IGF2BP2;IGF2BP3;KHDRBS2;LIN28A;MBNL2;MOV10;MSI2;NOP58;PRPF8;PTBP1;RBFOX2;SRSF1;SRSF9;TAF15;TARDBP;U2AF2;UPF1NAMacrophages_M2GSVA_HALLMARK_SPERMATOGENESIS

More results



Top

5. Enriched editing regions and immune infiltration for ZNF737


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
ENSG00000237440.7,ZNF737ACCEAGMacrophages_M05.6529e-030.3935image
chr19:20536516-20537836:-BLCAEERB_cells_memory1.6666e-02-0.2653image
chr19:20540507-20542531:-BLCAEERT_cells_CD82.1161e-020.1676image
ENSG00000237440.7,ZNF737BLCAEAGMacrophages_M11.2098e-020.1678image
chr19:20536516-20537836:-BRCAEERB_cells_naive3.8504e-02-0.1976image
chr19:20540507-20542531:-BRCAEERT_cells_CD4_memory_resting2.5894e-02-0.0841image
ENSG00000237440.7,ZNF737BRCAEAGT_cells_CD4_memory_resting1.0607e-02-0.0893image
ENSG00000237440.7,ZNF737COADEAGMast_cells_activated3.4834e-030.4017image
ENSG00000237440.7,ZNF737DLBCEAGMacrophages_M21.4795e-020.5362image
chr19:20540507-20542531:-ESCAEERMacrophages_M14.2531e-020.4360image
ENSG00000237440.7,ZNF737GBMEAGNeutrophils1.2596e-02-0.2680image
ENSG00000237440.7,ZNF737KICHEAGEosinophils7.5007e-040.4374image
chr19:20536516-20537836:-KIRCEERMacrophages_M15.8963e-030.3841image
chr19:20539012-20539300:-KIRCEERT_cells_CD4_memory_activated2.6842e-020.2507image
ENSG00000237440.7,ZNF737KIRCEAGT_cells_regulatory_(Tregs)2.9800e-030.1726image
chr19:20540507-20542531:-KIRPEERT_cells_CD4_memory_activated6.2379e-060.3903image
ENSG00000237440.7,ZNF737KIRPEAGMacrophages_M16.1823e-030.2098image
chr19:20540507-20542531:-LGGEERDendritic_cells_activated3.0079e-020.1346image
ENSG00000237440.7,ZNF737LGGEAGDendritic_cells_activated2.0943e-030.1551image
ENSG00000237440.7,ZNF737LIHCEAGDendritic_cells_resting3.2335e-020.4797image
chr19:20540507-20542531:-LUADEERB_cells_memory2.4276e-020.1643image
ENSG00000237440.7,ZNF737LUADEAGB_cells_memory3.0237e-020.1429image
chr19:20536516-20537836:-OVEERMast_cells_activated4.1567e-020.2375image
chr19:20539012-20539300:-OVEEREosinophils1.3152e-050.4206image
chr19:20536516-20537836:-PCPGEERDendritic_cells_resting7.5756e-030.5024image
chr19:20540507-20542531:-PCPGEERMacrophages_M11.2531e-020.2152image
ENSG00000237440.7,ZNF737PCPGEAGMacrophages_M11.8753e-020.2006image
chr19:20540507-20542531:-PRADEERDendritic_cells_activated1.2576e-030.1673image
ENSG00000237440.7,ZNF737PRADEAGT_cells_regulatory_(Tregs)4.2142e-020.0959image
ENSG00000237440.7,ZNF737READEAGMonocytes2.4654e-02-0.4774image
ENSG00000237440.7,ZNF737SARCEAGT_cells_CD4_memory_activated4.0454e-030.3816image
ENSG00000237440.7,ZNF737SKCMEAGNK_cells_resting1.5707e-040.5754image
chr19:20536516-20537836:-STADEERNeutrophils1.7420e-020.3995image
ENSG00000237440.7,ZNF737TGCTEAGB_cells_naive2.1257e-04-0.3255image
chr19:20536516-20537836:-THCAEERNeutrophils2.6355e-060.6251image
chr19:20539012-20539300:-THCAEERT_cells_CD4_memory_resting3.3309e-020.1398image
chr19:20540507-20542531:-THCAEERDendritic_cells_activated9.8869e-030.1223image
ENSG00000237440.7,ZNF737THCAEAGDendritic_cells_activated1.3971e-020.1124image
ENSG00000237440.7,ZNF737THYMEAGT_cells_CD83.9776e-02-0.2114image
chr19:20539012-20539300:-UCECEERT_cells_CD4_memory_resting2.9717e-02-0.4746image
chr19:20540507-20542531:-UCECEERT_cells_regulatory_(Tregs)4.0130e-020.2121image
ENSG00000237440.7,ZNF737UCSEAGMacrophages_M09.8690e-040.6292image


Top

6. Enriched editing regions and immune gene sets for ZNF737


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
ENSG00000237440.7,ZNF737ACCGSVA_HALLMARK_G2M_CHECKPOINTEAG1.2491e-020.3580image
chr19:20540507-20542531:-ACCGSVA_HALLMARK_MITOTIC_SPINDLEEER2.4921e-020.3733image
chr19:20536516-20537836:-BLCAGSVA_HALLMARK_TGF_BETA_SIGNALINGEER1.0370e-020.2834image
chr19:20540507-20542531:-BLCAGSVA_HALLMARK_KRAS_SIGNALING_DNEER1.5453e-030.2288image
ENSG00000237440.7,ZNF737BLCAGSVA_HALLMARK_KRAS_SIGNALING_DNEAG1.8865e-060.3128image
ENSG00000237440.7,ZNF737BRCAGSVA_HALLMARK_MYC_TARGETS_V2EAG3.7034e-020.0729image
chr19:20540507-20542531:-BRCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.1601e-020.0952image
ENSG00000237440.7,ZNF737COADGSVA_HALLMARK_DNA_REPAIREAG1.3092e-03-0.4379image
ENSG00000237440.7,ZNF737DLBCGSVA_HALLMARK_TGF_BETA_SIGNALINGEAG8.5411e-03-0.5711image
ENSG00000237440.7,ZNF737ESCAGSVA_HALLMARK_TGF_BETA_SIGNALINGEAG3.1232e-02-0.3700image
ENSG00000237440.7,ZNF737GBMGSVA_HALLMARK_APICAL_SURFACEEAG2.2674e-020.2456image
chr19:20540507-20542531:-GBMGSVA_HALLMARK_APICAL_SURFACEEER1.0150e-030.3899image
ENSG00000237440.7,ZNF737KICHGSVA_HALLMARK_HYPOXIAEAG1.3096e-020.3297image
chr19:20536516-20537836:-KIRCGSVA_HALLMARK_HEDGEHOG_SIGNALINGEER1.8274e-020.3326image
chr19:20540507-20542531:-KIRCGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEER3.3462e-040.2335image
chr19:20539012-20539300:-KIRCGSVA_HALLMARK_KRAS_SIGNALING_DNEER2.3763e-030.3393image
ENSG00000237440.7,ZNF737KIRCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG5.1445e-030.1628image
ENSG00000237440.7,ZNF737KIRPGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG9.3668e-030.1993image
chr19:20540507-20542531:-KIRPGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER4.7933e-020.1766image
ENSG00000237440.7,ZNF737LGGGSVA_HALLMARK_HEME_METABOLISMEAG1.0728e-030.1648image
chr19:20540507-20542531:-LGGGSVA_HALLMARK_UV_RESPONSE_DNEER6.6692e-040.2097image
ENSG00000237440.7,ZNF737LIHCGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG2.4076e-020.5021image
chr19:20540507-20542531:-LUSCGSVA_HALLMARK_PANCREAS_BETA_CELLSEER4.9992e-020.2787image
ENSG00000237440.7,ZNF737MESOGSVA_HALLMARK_IL2_STAT5_SIGNALINGEAG7.9724e-03-0.4910image
chr19:20540507-20542531:-OVGSVA_HALLMARK_COAGULATIONEER1.6170e-020.1620image
chr19:20539012-20539300:-OVGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER6.7084e-040.3345image
ENSG00000237440.7,ZNF737OVGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG1.0130e-02-0.1660image
chr19:20536516-20537836:-OVGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEER2.2458e-020.2651image
ENSG00000237440.7,ZNF737PAADGSVA_HALLMARK_PEROXISOMEEAG4.0026e-02-0.3144image
ENSG00000237440.7,ZNF737PCPGGSVA_HALLMARK_APOPTOSISEAG3.8138e-030.2456image
chr19:20536516-20537836:-PCPGGSVA_HALLMARK_PEROXISOMEEER5.9493e-040.6178image
chr19:20540507-20542531:-PCPGGSVA_HALLMARK_MTORC1_SIGNALINGEER6.6824e-030.2332image
ENSG00000237440.7,ZNF737PRADGSVA_HALLMARK_ANDROGEN_RESPONSEEAG1.5833e-07-0.2443image
chr19:20539012-20539300:-PRADGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER2.3793e-030.2566image
chr19:20540507-20542531:-PRADGSVA_HALLMARK_HYPOXIAEER1.9182e-020.1219image
ENSG00000237440.7,ZNF737SARCGSVA_HALLMARK_MITOTIC_SPINDLEEAG4.9544e-020.2661image
ENSG00000237440.7,ZNF737STADGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEAG3.1635e-020.1924image
chr19:20536516-20537836:-STADGSVA_HALLMARK_BILE_ACID_METABOLISMEER5.3995e-030.4603image
ENSG00000237440.7,ZNF737TGCTGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG5.5597e-050.3524image
chr19:20540507-20542531:-THCAGSVA_HALLMARK_HYPOXIAEER6.6150e-060.2120image
chr19:20539012-20539300:-THCAGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEER1.2731e-020.1633image
ENSG00000237440.7,ZNF737THCAGSVA_HALLMARK_APOPTOSISEAG5.0814e-090.2633image
chr19:20540507-20542531:-THYMGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEER4.5621e-030.3179image
chr19:20539012-20539300:-UCECGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER1.7110e-030.6418image


Top

7. Enriched editing regions and drugs for ZNF737


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000237440.7,ZNF737ACCGemcitabineEAG2.6746e-03-0.4240image
chr19:20540507-20542531:-ACCAZD6482EER3.9723e-03-0.4683image
ENSG00000237440.7,ZNF737BLCAAICAREAG4.4409e-06-0.3018image
chr19:20540507-20542531:-BLCAEHT.1864EER9.5214e-040.2385image
ENSG00000237440.7,ZNF737BRCAKU.55933EAG9.1714e-04-0.1157image
chr19:20540507-20542531:-BRCAJNK.Inhibitor.VIIIEER1.5128e-02-0.0917image
ENSG00000237440.7,ZNF737COADCCT007093EAG1.0882e-03-0.4444image
ENSG00000237440.7,ZNF737DLBCMG.132EAG3.4478e-02-0.4746image
chr19:20540507-20542531:-ESCAGefitinibEER4.0039e-030.5880image
ENSG00000237440.7,ZNF737ESCADocetaxelEAG9.4915e-03-0.4385image
chr19:20540507-20542531:-GBMKU.55933EER2.4329e-02-0.2729image
ENSG00000237440.7,ZNF737GBMKU.55933EAG9.9137e-03-0.2767image
ENSG00000237440.7,ZNF737KICHABT.888EAG2.4860e-03-0.3965image
chr19:20536516-20537836:-KIRCBortezomibEER3.9307e-020.2924image
chr19:20540507-20542531:-KIRCCI.1040EER1.4944e-02-0.1596image
ENSG00000237440.7,ZNF737KIRCMetforminEAG1.9627e-04-0.2155image
ENSG00000237440.7,ZNF737KIRPJNK.9LEAG1.3568e-04-0.2894image
chr19:20540507-20542531:-KIRPDMOGEER2.0823e-04-0.3246image
chr19:20540507-20542531:-LGGAZD6482EER7.4959e-04-0.2078image
ENSG00000237440.7,ZNF737LGGCamptothecinEAG2.7058e-030.1513image
ENSG00000237440.7,ZNF737LIHCGW.441756EAG2.8797e-020.4887image
chr19:20539012-20539300:-LUADCCT018159EER2.5578e-04-0.5475image
chr19:20540507-20542531:-LUSCJNK.Inhibitor.VIIIEER4.4174e-02-0.2859image
ENSG00000237440.7,ZNF737MESOBIRB.0796EAG1.7964e-03-0.5634image
chr19:20536516-20537836:-OVBI.2536EER7.6843e-030.3076image
ENSG00000237440.7,ZNF737OVAZ628EAG2.9949e-05-0.2665image
chr19:20540507-20542531:-OVAZ628EER7.0980e-05-0.2646image
chr19:20539012-20539300:-OVCCT007093EER8.5455e-040.3283image
ENSG00000237440.7,ZNF737PAADAP.24534EAG3.0391e-02-0.3306image
chr19:20540507-20542531:-PCPGAxitinibEER1.4130e-030.2730image
chr19:20536516-20537836:-PCPGJNK.9LEER1.6904e-03-0.5754image
ENSG00000237440.7,ZNF737PCPGBosutinibEAG6.9878e-040.2862image
ENSG00000237440.7,ZNF737PRADCyclopamineEAG9.7612e-06-0.2103image
chr19:20540507-20542531:-PRADDasatinibEER8.5290e-04-0.1736image
ENSG00000237440.7,ZNF737READAZ628EAG1.8828e-02-0.4962image
ENSG00000237440.7,ZNF737SARCCytarabineEAG2.6798e-030.3972image
ENSG00000237440.7,ZNF737SKCMBMS.708163EAG1.5047e-020.3916image
ENSG00000237440.7,ZNF737STADGSK269962AEAG3.4510e-04-0.3163image
chr19:20540507-20542531:-STADCI.1040EER1.5831e-02-0.2724image
ENSG00000237440.7,ZNF737TGCTBI.D1870EAG2.8384e-050.3651image
chr19:20536516-20537836:-THCACCT018159EER2.0427e-05-0.5786image
chr19:20540507-20542531:-THCAAICAREER1.5183e-03-0.1501image
ENSG00000237440.7,ZNF737THCALFM.A13EAG1.0692e-08-0.2578image
chr19:20539012-20539300:-THCAMetforminEER6.2918e-050.2596image
chr19:20540507-20542531:-THYMJNJ.26854165EER2.7239e-02-0.2501image
ENSG00000237440.7,ZNF737UCECA.770041EAG6.2799e-06-0.4157image
chr19:20539012-20539300:-UCECCisplatinEER3.8547e-03-0.6024image
chr19:20540507-20542531:-UCECFH535EER8.5975e-03-0.2696image
ENSG00000237440.7,ZNF737UCSAUY922EAG1.4342e-03-0.6134image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType